The data also show the safety and the high specificity of the NK-1R antagonist aprepitant to treat AML: the damage induced by aprepitant in cancer cells is higher than that exerted in non-cancer cells (the IC50 for lymphocytes is ten-fold higher than that for AML cells). Here, TACR1 is linked to acute myeloid leukemia.